Dmitri Bobilev
Director Técnico/Científico/I+D en FUSN PHAR .
Cargos activos de Dmitri Bobilev
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
FUSN PHAR | Director Técnico/Científico/I+D | 07/11/2022 | - |
Historial de carrera de Dmitri Bobilev
Antiguos cargos conocidos de Dmitri Bobilev.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/06/2018 | 01/08/2020 |
CHECKMATE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Formación de Dmitri Bobilev.
Omsk State Medical Academy | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Canadá | 2 |
2 |
Operativa
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant in 2014 and is headquartered in Hamilton, Canada. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Dmitri Bobilev
- Experiencia